INCOME TAXES (Tables)
|
12 Months Ended |
Dec. 31, 2022 |
| Income Tax Disclosure [Abstract] |
|
| SCHEDULE OF INCOME TAXES BENEFIT |
Loss
before provision for income taxes consisted of the following:
SCHEDULE OF INCOME TAXES BENEFIT
| | |
Year ending December 31, | |
| | |
2022 | | |
2021 | |
| United States | |
$ | ) | |
$ | ) |
|
| SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) |
The
federal and state income tax provision (benefit), included in general and administrative expenses in the Consolidated Statement of Operations,
is summarized as follows:
SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT)
| | |
Year ending December 31, | |
| | |
2022 | | |
2021 | |
| Current state provision | |
| - | | |
$ | 1,600 | |
|
| SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION |
The
effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows:
SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION
| | |
| | | |
| | |
| | |
Year ending December 31, | |
| | |
2022 | | |
2021 | |
| Income (benefit) taxes at statutory rates | |
| (5,083,614 | ) | |
| (6,120,640 | ) |
| State income tax, net of federal benefit | |
| (175,164 | ) | |
| (131,962 | ) |
| Warrants and convertible debt | |
| (234,214 | ) | |
| 1,620,341 | |
| Nondeductible executive compensation | |
| - | | |
| 480,248 | |
| Stock based compensation | |
| 303,499 | | |
| (278,940 | ) |
| Share subscription facility transaction costs | |
| 20,335 | | |
| 2,664,850 | |
| Research and development tax credits | |
| (1,028,988 | ) | |
| (501,451 | ) |
| Change in tax rates | |
| 54,263 | | |
| 371,784 | |
| Other | |
| (78,227 | ) | |
| (139,213 | ) |
| Change in valuation allowance | |
| 6,222,110 | | |
| 2,034,983 | |
| Total | |
| - | | |
| - | |
|
| SCHEDULE OF DEFERRED TAX ASSETS |
The
Company’s deferred tax assets were comprised of the following:
SCHEDULE OF DEFERRED TAX ASSETS
| | |
| | | |
| | |
| | |
As of December 31, | |
| | |
2022 | | |
2021 | |
| Deferred tax assets: | |
| | | |
| | |
| Net operating loss tax carryforwards | |
$ | 26,726,066 | | |
$ | 25,068,127 | |
| Tax credits | |
| 4,164,187 | | |
| 3,164,799 | |
| Capitalized research costs | |
| 3,729,483 | | |
| - | |
| Stock-based compensation | |
| 1,173,158 | | |
| 915,675 | |
| Other | |
| 265,677 | | |
| 687,422 | |
| Deferred Tax Assets, Gross | |
| 36,058,571 | | |
| 29,836,023 | |
| Valuation allowance | |
| (36,052,644 | ) | |
| (29,830,534 | ) |
| Total deferred tax assets | |
| 5,927 | | |
| 5,489 | |
| Deferred tax liabilities: | |
| | | |
| | |
| Convertible notes: embedded derivatives | |
| - | | |
| - | |
| Other | |
| (5,927 | ) | |
| (5,489 | ) |
| Total deferred tax liabilities | |
| (5,927 | ) | |
| (5,489 | ) |
| Net deferred tax assets | |
$ | - | | |
$ | - | |
|
| SUMMARY OF INCOME TAX CONTINGENCIES |
The
following table summarizes the activity related to the Company’s unrecognized tax benefits:
SUMMARY OF INCOME TAX CONTINGENCIES
| | |
| | | |
| | |
| | |
Year ending December 31, | |
| | |
2022 | | |
2021 | |
| Balance at beginning of year | |
| 1,135,179 | | |
| 968,445 | |
| Increases related to current year tax positions | |
| 341,108 | | |
| 171,977 | |
| Decreases related to prior year tax positions | |
| (48,026 | ) | |
| (5,243 | ) |
| Balance at end of year | |
| 1,428,261 | | |
| 1,135,179 | |
|